Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway

• Autores principales: Wanguo Yu (Autor), Yaxin Gao (Autor), Zaoya Zhao (Autor), Xiufeng Long (Autor), Yi Yi (Autor), Shuo Ai (Autor)
• Formato: Libro
• Publicado: BMC, 2023-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Background Non-alcoholic fatty liver disease (NAFLD) has been well defined as a common chronic liver metabolism disorder. Statins as a first-line therapeutic treatment had some side effects. Here, we found that Fumigaclavine C (FC) was collected from endophytic Aspergillus terreus via the r...